How does the patient's response affect yervoy dosage?

In general, ipilimumab (Yervoy) dosing is not adjusted based on how well the tumor responds. The dose is fixed and based on weight per cycle, and the total number of cycles is usually predefined (e.g., 4 doses given every 3 weeks for metastatic melanoma). How the cancer responds does not typically change the amount given per infusion.

Key points:
- Standard practice: dose per cycle remains the same (weight-based) regardless of response.
- Treatment duration: you may complete the planned number of cycles, or stop early if there is a durable complete/partial response or if toxicity is unacceptable.
- If progression occurs: ipilimumab is usually discontinued.
- If immune-related side effects occur: therapy may be held or stopped, and management is based on toxicity rather than dose reduction. After resolution, some patients may be resumed at the same dose, or discontinued, depending on the severity and physician judgment.
- There are different regimens for different cancers or settings (e.g., adjuvant therapy), so exact dosing can vary by indication.

If you’re asking for a specific patient’s plan, please share the cancer type and regimen being used, and I can tailor the details. Always follow your oncologist’s dosing instructions.